Tulisokibart – Patient Worthy

Merck & Co Launches Phase IIb Trials of Tulisokibart in Rheumatoid Arthritis and Other Inflammatory Diseases

Post author:Bree Clare
Post published:November 4, 2025
Post category:Rheumatoid Arthritis

Merck & Co has taken a significant step forward in its immunology pipeline by initiating Phase IIb clinical studies for tulisokibart (MK-7240), its investigational therapy targeting immune-mediated inflammatory diseases. According…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More